(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22nd to the 24th of March, 2017. …

Presentation details are as follows: #4455 Poster Session on December 6, 2016 between 2:30 – 3:45PM (Hall B) Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous nonsmall cell lung cancer patients Author(s): Rodryg Ramlau, Dariusz Kowalski, Cezary Szczylik, Aleksandra Szczęsna, Elzbieta Wiatr, Steve Demas, Heman Chao, Kazimierz Roszkowski-Sliz

CAR-T cells harboring a camelid single domain antibody as a targeting agent to CEACAM6 antigen in pancreatic cancer

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. Heman Chao, Helix’s CSO, will be presenting: Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer at the Precision Lung …